Resectable Esophageal Squamous Cell Carcinoma
7 clinical trials · Condition
◉ Watch Resectable Esophageal Squamous Cell Carcinoma
| Record | Firm | Date |
|---|---|---|
| A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma (NCT04533490) | The First Affiliated Hospital of Zhengzhou University | 2021-10-01 |
| Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC. (NCT05043688) | Zhigang Li | 2021-09-01 |
| Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma (NCT04974047) | BeiGene | 2021-08-17 |
Track Resectable Esophageal Squamous Cell Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.